N+1 Singer Reiterates “Corporate” Rating for Ekf Diagnostics Holding PLC (EKF)
Ekf Diagnostics Holding PLC (LON:EKF)‘s stock had its “corporate” rating reiterated by analysts at N+1 Singer in a report released on Friday.
Several other analysts have also weighed in on EKF. Panmure Gordon reissued a “buy” rating and issued a GBX 14 ($0.17) target price on shares of Ekf Diagnostics Holding PLC in a report on Wednesday, July 6th. FinnCap reissued an “under review” rating on shares of Ekf Diagnostics Holding PLC in a report on Tuesday, August 30th.
Ekf Diagnostics Holding PLC (LON:EKF) opened at 17.6875 on Friday. Ekf Diagnostics Holding PLC has a 52-week low of GBX 7.00 and a 52-week high of GBX 23.45. The firm has a 50-day moving average price of GBX 15.02 and a 200 day moving average price of GBX 13.29. The firm’s market capitalization is GBX 75.84 million.
In related news, insider Mills,Christopher H. B acquired 9,000,000 shares of Ekf Diagnostics Holding PLC stock in a transaction dated Friday, July 15th. The shares were acquired at an average cost of GBX 15 ($0.19) per share, for a total transaction of £1,350,000 ($1,670,792.08).
Ekf Diagnostics Holding PLC Company Profile
EKF Diagnostics Holdings Plc is focused on the In-Vitro Diagnostic device (IVD) market place. The Company is engaged in the designing, development, manufacture and selling of diagnostic instruments, reagents and certain ancillary products. This activity takes place across various geographical locations which include the United States America, Germany, Poland, Russia, United Kingdom and Ireland.
Receive News & Ratings for Ekf Diagnostics Holding PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekf Diagnostics Holding PLC and related companies with MarketBeat.com's FREE daily email newsletter.